May 5, 2020 / 5:58 AM / a month ago

BRIEF-Vicore Pharma Gets Regulatory Approval To Start Phase II Clinical Trial With VP01

May 5 (Reuters) - Vicore Pharma Holding AB:

* VICORE PHARMA RECEIVES REGULATORY APPROVAL TO START PHASE II CLINICAL TRIAL WITH VP01 (C21) IN PATIENTS WITH IPF

* ANNOUNCES APPROVAL BY UK REGULATORY AGENCY (MHRA(1)) OF CLINICAL TRIAL APPLICATION (CTA) FOR A PHASE II STUDY WITH ITS PROPRIETARY COMPOUND VP01 (C21) IN PATIENTS WITH IPF (IDIOPATHIC PULMONARY FIBROSIS)

* DEPENDING ON COVID-19 SITUATION, VICORE PHARMA ANTICIPATES THAT PATIENT RECRUITMENT MAY START DURING Q3 OF 2020 Source text for Eikon: Further company coverage: (Gdansk Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below